MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Income Overview

Revenue
$148K
Net Income
-$66,955K
Net Profit Margin
-45239.86%
EPS
-$2.32
Unit: Thousand (K) dollars

Income Statement
2026-06-30
Collaboration revenue
148
Research and development cost
39,377
General and administrative
11,657
Total operating expenses
51,034
Loss from operations
-50,886
Interest income
4,189
Interest expense
210
Sublease income - related party
0
Change in fair value of simple agreement for future equity
5,556
Total other (expense) income, net
-1,577
Net loss
-52,463
Cumulative dividends on convertible preferred stock
14,492
Deemed dividend upon down-round of convertible preferred stock
0
Net loss allocable to common stockholders
-66,955
Basic EPS
-2.32
Diluted EPS
-2.32
Basic Average Shares
28,908,277
Diluted Average Shares
28,908,277
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

Net loss allocableto common...-$66,955K Net loss-$52,463K Cumulative dividends onconvertible preferred stock$14,492K Loss from operations-$50,886K Total other (expense)income, net-$1,577K Collaboration revenue$148K Interest income$4,189K Total operatingexpenses$51,034K Change in fair value ofsimple agreement for...$5,556K Interest expense$210K Research and developmentcost$39,377K General andadministrative$11,657K

Parabilis Medicines, Inc. (PBLS)

Parabilis Medicines, Inc. (PBLS)